The first-in-patient study of EP102, our lead METTL3 inhibitor, marks a major milestone for EPICS Therapeutics, and for the field of RNA epigenetics.
EPICS is prioritizing cancers where METTL3 dysregulation and DNA damage response pathways intersect, a setting where existing therapies are often insufficient.
- NSCLC: Despite advances in targeted and immune therapies, many patients relapse, highlighting a need for new mechanisms of action.
- Pancreatic cancer: Among the deadliest cancers, with limited effective therapies and a 5-year relative survival of 3%
- Ovarian cancer: High recurrence rates and resistance to standard regimens create urgent unmet needs.
- Colorectal cancer: A leading cause of cancer mortality, where treatment resistance and disease progression remain major clinical challenges.
By targeting METTL3, EP102 introduces a new mechanism of action aimed at restoring control over tumor growth and treatment resistance.
